Serum levels of soluble syndecan-1 in Hodgkin's lymphoma
Vassilakopoulos, T.P.; Kyrtsonis, M-Christine.; Papadogiannis, A.; Nadali, G.; Angelopoulou, M.K.; Tzenou, T.; Dimopoulou, M.N.; Siakantaris, M.P.; Kontopidou, F.N.; Kalpadakis, C.; Kokoris, S.I.; Dimitriadou, E.M.; Tsaftaridis, P.; Pizzolo, G.; Pangalis, G.A.
Anticancer Research 25(6c): 4743-4746
2005
ISSN/ISBN: 0250-7005 PMID: 16334170 Document Number: 591817
Background: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Stembeig (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL. Patients and Methods: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-inatched healthy individuals. Results: The levels of syndecan-1 were higher in HL patients than controls (100.2 +/- 35.9 ng/ml vs. 67.9 +/- 24.5 ng/ml, p<0.001). They marginally correlated with advanced age (p=0.06), male gender (p = 0.07) and consequently high IPS (p = 0. 01), but did not con-elate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70 +/- 9% vs. 50 +/- 11% (p=0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml. Conclusion: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.